Almost every headline about compounded semaglutide and tirzepatide in the last eighteen months has pointed at the FDA — the shortage-list resolutions, the 503B bulks proposal, the advisory committee vote in July. That is the floor. It is not the whole building.
A survey published in the National Law Review on August 6, 2026 lays out the layer above it, and the picture is less uniform than the federal story suggests. One state has written a stricter standard into its own regulations. Two more got to roughly the same place through enforcement without writing anything new. Several issued position statements with no rules attached. Two of the largest states did nothing GLP-1-specific at all. Where a compounded prescription is filled now changes what can be in it.
Research-context information only. This article reports on published state regulations, board guidance, and enforcement records. Nothing here is medical or legal advice. Semaglutide, tirzepatide, and liraglutide are FDA-approved as prescription medicines; the research-use-only material sold by peptide vendors is not FDA-approved for human use and has not been evaluated for safety, purity, or potency in that channel. Retatrutide and cagrilintide are investigational and are not approved for any use in humans in the United States. Consult a licensed physician for personal medical decisions.
California is the one state that wrote it down
The California State Board of Pharmacy adopted a comprehensive rewrite of its compounding regulations on June 17, 2025, codified at 16 CCR §§ 1735.1, 1736.1, 1735.8 and 1736.8, with the rewritten framework taking effect October 1, 2025.
The operative change is to the "essentially a copy" analysis — the test that determines whether a pharmacy may compound something that shares an active ingredient with a commercially available drug. Federal 503A guidance asks whether the compounded product produces a "significant difference" for the patient. California's version asks for a clinically significant difference, and it requires that difference to be documented twice: a prescriber rationale identifying the formulation change and its expected clinical impact, and a separate pharmacist verification explaining why that change is clinically significant for that individual. Supporting evidence — allergy documentation, adverse-reaction history, comparative product data — has to be retained in readily retrievable form.
Two details make the California rule harder to satisfy than the federal one. It attaches no exception based on dosage strength, route of administration, or commercial availability, so the common workaround of compounding an off-label strength does not clear the bar on its own. And per the National Law Review survey, California-specific conditions require a certificate of analysis to name the actual manufacturer of the active ingredient rather than the distributor that supplied it — a sourcing-transparency requirement with no federal counterpart.
Ohio and Washington got there without new rules
Ohio never passed a GLP-1 statute. On July 17, 2025 its Board of Pharmacy published FAQs interpreting the existing compounding chapters — 4729:7-2 for pharmacies, 4729:7-3 for prescribers, 4729:6-10 for outsourcing facilities — against the post-shortage landscape.
The FAQs took the position that compounding is appropriate only where the drug is not commercially available, or where the compounded version carries a patient-specific change producing a significant difference. The line that did the most work: "a prescription that identifies only a patient's name and drug product formulation is not sufficient to establish that the prescriber made the determination." Adding B12 or a similar ingredient was called out as insufficient justification on its own.
Then the board enforced it. Ohio Capital Journal reporting through 2025 documented a rolling series of suspensions of licenses to distribute dangerous drugs held by med spas, weight-loss clinics and physician offices — clinics in Cleveland, Cincinnati, Dayton and Columbus suspended in January, four more in June, with the allegations including product carrying Chinese and Korean labels from firms not registered with the FDA, product relabeled on site, and in one case purchases direct from unlicensed manufacturers and from a consumer marketplace. Tirzepatide, semaglutide, liraglutide and retatrutide were all named in those orders. The National Law Review survey counts more than thirty clinics and medical spas suspended since early 2025 and describes Ohio as treating investigational peptides, including retatrutide and cagrilintide, as outside what may be compounded at all.
Washington followed a similar shape on a smaller scale. Its Pharmacy Quality Assurance Commission issued a semaglutide-specific compounding statement in August 2024, then moved on individual licensees — including a Limited Stop Service order against a GLP-1 compounding pharmacy that barred it from compounding, dispensing, delivering or distributing compounded products in the state until the underlying sterile-compounding deficiencies were corrected.
The tiers below that: statements, consumer protection, and nothing
Not every state that has spoken has done anything enforceable.
Position statements without new rules. Alabama and New Jersey issued statements prohibiting salt forms and requiring pharmaceutical-grade ingredients from FDA-registered sources accompanied by valid certificates of analysis. Both restate the federal position rather than exceeding it, which matters mainly because it signals where board attention sits.
Consumer-protection enforcement instead of pharmacy regulation. Connecticut, Illinois and South Carolina have pursued this through their consumer-protection statutes, targeting marketing claims — advertising that implies a compounded product is FDA-approved, or equivalent to the branded drug — rather than the act of compounding itself. That is a different lever with a different target: the telehealth platform or the clinic's advertising, not the pharmacy's formulation records.
The federal floor, unchanged. Texas and Florida, two of the largest compounding markets in the country, have no GLP-1-specific rules. Both rely on their general compounding frameworks, which incorporate the federal "essentially a copy" limitation and nothing further.
The practical upshot is that in most of the country, federal policy cascades directly. When the FDA moves a list, it moves everywhere except the handful of states that have built something on top.
What the state layer touches, and what it does not
State pharmacy boards regulate licensees. That is the boundary worth being precise about, because it explains why two channels that look similar from the outside respond to completely different news.
The prescribed and compounded route runs through a state license at every step — the pharmacy or outsourcing facility that prepares the product, the prescriber who ordered it, and increasingly the telehealth platform that arranged the visit. That route is what California's documentation standard, Ohio's FAQs, and Washington's stop-service orders act on. A reader in Ohio and a reader in Florida asking their clinic for the same compounded product are asking under different rules.
The research-use-only route does not run through a pharmacy license. Vendors selling on that basis are not compounding against a prescription, and the state rules described in this article do not reach them; nothing in the California rewrite or the Ohio FAQs changed anything about that channel in any state. That material is also not FDA-approved for human use and has not been evaluated for safety, purity or potency as sold — a distinction our research-peptide legality guide covers at the national level, with per-state status on the state-by-state legal pages.
For the research-use-only versions of these compounds — a separate channel from the prescribed and compounded route discussed above, and one that is not FDA-approved for human use — current vendor pricing per milligram, coupon status and COA availability sit on the buying surfaces:
